Cargando…
P1599: REAL-WORLD CLINICAL PRACTICES IN TREATMENT DISCONTINUATION WITH COMPLEMENT C5 INHIBITORS FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME: A GLOBAL SURVEY OF HEALTHCARE PROFESSIONALS
Autores principales: | Lo, Siu Hing, Aggio, Daniel, Gatta, Francesca, Ong, Moh-Lim, Wang, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430006/ http://dx.doi.org/10.1097/01.HS9.0000973272.98235.10 |
Ejemplares similares
-
Complement and the atypical hemolytic uremic syndrome in children
por: Loirat, Chantal, et al.
Publicado: (2008) -
Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?
por: Rodriguez, Eva, et al.
Publicado: (2017) -
Complements Spurned: Our Experience with Atypical Hemolytic Uremic Syndrome
por: Nagar, Vidya S., et al.
Publicado: (2017) -
Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics
por: Geerdink, Lianne M., et al.
Publicado: (2012) -
Evaluation of complement regulatory components in patients with atypical hemolytic uremic syndrome
por: Soudabeh, Hosseini, et al.
Publicado: (2014)